01 1Patheon Italia S.p.A.
01 1oritavancin diphosphate
01 1U.S.A
NDC Package Code : 68225-121
Start Marketing Date : 2021-03-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (1200mg/40mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
A Oritavancin Diphosphate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Oritavancin Diphosphate, including repackagers and relabelers. The FDA regulates Oritavancin Diphosphate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Oritavancin Diphosphate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Oritavancin Diphosphate supplier is an individual or a company that provides Oritavancin Diphosphate active pharmaceutical ingredient (API) or Oritavancin Diphosphate finished formulations upon request. The Oritavancin Diphosphate suppliers may include Oritavancin Diphosphate API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Oritavancin Diphosphate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Oritavancin Diphosphate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Oritavancin Diphosphate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Oritavancin Diphosphate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Oritavancin Diphosphate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Oritavancin Diphosphate suppliers with NDC on PharmaCompass.
We have 1 companies offering Oritavancin Diphosphate
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
